Growing community of inventors

Cologne, Germany

Gudrun Schiedner

Average Co-Inventor Count = 2.45

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 156

Gudrun SchiednerUdo Reichl (12 patents)Gudrun SchiednerChristoph Volpers (3 patents)Gudrun SchiednerStefan Kochanek (2 patents)Gudrun SchiednerSilke Wissing (1 patent)Gudrun SchiednerJens Wölfel (1 patent)Gudrun SchiednerHanns-Martin Schmidt (2 patents)Gudrun SchiednerHanns-Martin Schmidt (1 patent)Gudrun SchiednerThierry Vandendriessche (1 patent)Gudrun SchiednerMarinee Chuah (1 patent)Gudrun SchiednerMarkus Ribbert (1 patent)Gudrun SchiednerGudrun Schiedner (6 patents)Udo ReichlUdo Reichl (12 patents)Christoph VolpersChristoph Volpers (5 patents)Stefan KochanekStefan Kochanek (2 patents)Silke WissingSilke Wissing (6 patents)Jens WölfelJens Wölfel (3 patents)Hanns-Martin SchmidtHanns-Martin Schmidt (2 patents)Hanns-Martin SchmidtHanns-Martin Schmidt (1 patent)Thierry VandendriesscheThierry Vandendriessche (1 patent)Marinee ChuahMarinee Chuah (1 patent)Markus RibbertMarkus Ribbert (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Cevec Pharmaceuticals Gmbh (3 from 9 patents)

2. Baylor College of Medicine (1 from 601 patents)

3. Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (1 from 44 patents)

4. Cevec Pharmaceutical Gmbh (1 from 1 patent)


6 patents:

1. 11193156 - Recombinant glycoproteins with reduced antennary fucosylation

2. 9371512 - Method for the production of permanent human cell lines

3. 9315773 - Method for the production of permanent human cell lines

4. 8936908 - Method for the production of permanent human cell lines

5. 7238346 - High capacity recombinant adenoviral vector for treatment of hemophilia A

6. 5981225 - Gene transfer vector, recombinant adenovirus particles containing the

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/2/2026
Loading…